Metronomics chemotherapy: Time for computational decision support

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 3, 2014, Pages 647-652

  Barbolosi, Dominique ^a   Ciccolini, Joseph ^a   Meille, Christophe ^b   Elharrar, Xavier ^a,c,d   Faivre, Christian ^a   Lacarelle, Bruno ^a   André, Nicolas ^a,d,e   Barlesi, Fabrice ^a,c,d  

^a INSERM   (France)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c AIX MARSEILLE UNIVERSITY   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^e Metronomic Global Health Initiative Pediatric Oncology Unit   (France)

Author keywords

Computational oncology; Lung cancer; Metronomics; Modeling and simulation; Vinorelbine

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; NAVELBINE; TEMOZOLOMIDE;

ACUTE LEUKEMIA; ARTICLE; BLOOD TOXICITY; BREAST METASTASIS; CANCER CHEMOTHERAPY; CHILDHOOD CANCER; COMPUTER SIMULATION; DECISION SUPPORT SYSTEM; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG TOLERABILITY; ENDOTHELIUM CELL; HUMAN; LOW DRUG DOSE; LUNG CANCER; MATHEMATICAL MODEL; MAXIMUM TOLERATED DOSE; METRONOMIC DRUG ADMINISTRATION; MONOTHERAPY; NEUTROPENIA; PREDICTION; PRIORITY JOURNAL; REPEATED DRUG DOSE; RHABDOMYOSARCOMA; TUMOR GROWTH;

ADMINISTRATION, METRONOMIC; ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; DECISION SUPPORT SYSTEMS, CLINICAL; HUMANS; LUNG NEOPLASMS; VINBLASTINE;

EID: 84907361692     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2546-1     Document Type: Article

References (35)

1. Caffo O, Dipasquale M, Murgia V, Veccia A, Galligioni E (2013) An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment. Expert Opin Drug Metab Toxicol 9:1037-1051
2. Minard-Colin V, Ichante JL, Nguyen L, Paci A, Orbach D, Bergeron C, Defachelles AS, André N, Corradini N, Schmitt C, Tabone MD, Blouin P, Sirvent N, Goma G, Geoerger B, Oberlin O (2012) Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma - a report from the Société Française des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE). Eur J Cancer 48:2409-2416
3. Shukla N, Kobos R, Renaud T, Steinherz LJ, Steinherz PG (2014) Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia. Pediatr Blood Cancer 61:431-435
4. Galano G, Caputo M, Tecce MF, Capasso A (2011) Efficacy and tolerability of vinorelbine in the cancer therapy. Curr Drug Saf 6:185-193
5. Faller BA, Pandit TN (2011) Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer. Clin Med Insights Oncol 5:131-144
6. Aapro MS, Conte P, González EE, Trillet-Lenoir V (2007) Oral vinorelbine: role in the management of metastatic breast cancer. Drugs 67:657-667 (Pubitemid 46535641)
7. André N, Padovani L, Verschuur A (2010) Metronomic chemotherapy: back to the future. Drug News Perspect 23:143-151
8. Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U (2013) Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer 49:3387-3395
9. Briasoulis E, Pappas P, Puozzo C, Tolis C, Fountzilas G, Dafni U, Marselos M, Pavlidis N (2009) Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res 15:6454-6461
10. Pallis AG, Chandrinos V, Pavlakou G, Xenidis N, Varthalitis I, Vardakis N, Vamvakas L, Kontopodis E, Rovithi M, Georgoulias V (2011) A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC. Cancer Chemother Pharmacol 67:1239-1245
11. Addeo R, Sgambato A, Cennamo G, Montella L, Faiola V, Abbruzzese A, Capasso E, Leo L, Botti G, Caraglia M, Del Prete S (2010) Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer 10:301-306
12. Rajdev L, Negassa A, Dai Q, Goldberg G, Miller K, Sparano JA (2011) Phase I trial of metronomic oral vinorelbine in patients with advanced cancer. Cancer Chemother Pharmacol 68:1119-1124
13. Saloustros E, Kalbakis K, Vardakis N, Kalykaki A, Milaki G, Rovithi M, Agelaki S, Saridaki Z, Georgoulias V, Mavroudis D (2011) Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer. J BUON 16:215-218
14. Saridaki Z, Malamos N, Kourakos P, Polyzos A, Ardavanis A, Androulakis N, Kalbakis K, Vamvakas L, Georgoulias V, Mavroudis D (2012) A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 69:35-42
15. Addeo R, Sperlongano P, Montella L, Vincenzi B, Carraturo M, Iodice P, Russo P, Parlato C, Salzano A, Cennamo G, Lombardi A, Sperlongano R, Prete SD, Caraglia M (2012) Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. Cancer Chemother Pharmacol 70:603-609
16. Kontopodis E, Hatzidaki D, Varthalitis I, Kentepozidis N, Giassas S, Pantazopoulos N, Vardakis N, Rovithi M, Georgoulias V, Agelaki S (2013) A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group. J Chemother 25:49-55
17. Briasoulis E, Aravantinos G, Kouvatseas G, Pappas P, Biziota E, Sainis I, Makatsoris T, Varthalitis I, Xanthakis I, Vassias A, Klouvas G, Boukovinas I, Fountzilas G, Syrigos KN, Kalofonos H, Samantas E (2013) Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer 13:263
18. Cazzaniga ME, Torri V, Villa F, Giuntini N, Riva F, Zeppellini A, Cortinovis D, Bidoli P (2014) Efficacy and safety of the all-oral schedule of metronomic vinorelbine and capecitabine in locally advanced or metastatic breast cancer patients: the phase I-II VICTOR-1 study. Int J Breast Cancer 2014:769790
19. Mukherjee A, Majumder D (2008) Mathematical modelling for the assessment of the effect of drug application delays in metronomic chemotherapy of cancer due to physiological constraints. Biosystems 91:108-116 (Pubitemid 350297569)
20. Panetta JC, Schaiquevich P, Santana VM, Stewart CF (2008) Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. Clin Cancer Res 14:318-325 (Pubitemid 351378008)
21. Faivre C, Barbolosi D, Pasquier E, André N (2013) A mathematical model for the administration of temozolomide: comparative analysis of conventional and metronomic chemotherapy regimens. Cancer Chemother Pharmacol 71:1013-1019
22. Rygaard K, Spang-Thomsen M (1997) Quantitation and gompertzian analysis of tumor growth. Breast Cancer Res Treat 46:303-312 (Pubitemid 28029530)
23. Kerbel RS (2009) Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. Breast 8:S41-S47
24. Dimova I, Popivanov G, Djonov V (2014) Angiogenesis in cancer-general pathways and their therapeutic implications. J BUON 19:15-21
25. Meille C, Iliadis A, Barbolosi D, Frances N, Freyer G (2008) An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics. J Pharmacokinet Pharmacodyn 35:619-633
26. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713-4721 (Pubitemid 36025290)
27. Meille C, Gentet JC, Barbolosi D, André N, Doz F, Iliadis A (2008) New adaptive method for phase I trials in oncology. Clin Pharmacol Ther 83:873-881 (Pubitemid 351704918)
28. Marouani H, Woloch C, Benay S, Frances N, Iliadis A (2012) Progress in strategies for dosage regimen individualization. Curr Top Med Chem 12:1669-1677
29. Tsimberidou AM, Eggermont AM, Schilsky RL (2014) Precision cancer medicine: the future is now, only better. Am Soc Clin Oncol Educ Book. 61-9
30. Agur Z, Elishmereni M, Kheifetz Y (2014) Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: mathematics, statistics, and their integration. Wiley Interdiscip Rev Syst Biol Med 6: 239-53
31. Lee JJ, Chu CT (2012) Bayesian clinical trials in action. Stat Med 31:2955-2972
32. Mercier C, Ciccolini J, Pourroy B, Fanciullino R, Duffaud F, Digue L, Tranchand B, Monjanel-Mouterde S, Guillet P, Nicoara A, Baciuchka M, Bagarry-Liegey D, Lacarelle B, Noble A, Durand A, Favre R (2006) Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities. Ther Drug Monit 28:212-218 (Pubitemid 44314951)
33. Chen CS, Doloff JC, Waxman DJ (2014) Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression. Neoplasia 16:84-96
34. André N, Carré M, Pasquier E (2014) Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol 11:413-431
35. Pasquier E, Kavallaris M, André N (2010) Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7:455-465